TITLE

The Industry

PUB. DATE
March 2008
SOURCE
Pharmaceutical Representative;Mar2008, Vol. 38 Issue 3, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. KV Pharmaceutical Co. is purchasing the worldwide rights of Gestiva, a 17-alpha hydroxyprogesterone caproate from Hologic Inc. Teva Specialty Pharmaceuticals and Smyrna have agreed to jointly commercialize the respiratory medicines from Teva. GlaxoSmithKline has formed a partnership with Santaris Pharma A/S for commercialization of potential therapies for viral diseases.
ACCESSION #
31184186

 

Related Articles

  • Global Deals Network: In Detail.  // BioPharm International;Sep2006, Vol. 19 Issue 9, p16 

    The article offers information on deals involving pharmaceutical firms. Enzon Pharmaceuticals Inc. and Santaris Pharma A/S have agreed to co-develop and market a series of RNA antagonists based on Santaris' technology. AstraZeneca PLC and Isogenica Ltd. will collaborate on discovering peptides....

  • Other News To Note.  // BioWorld Today;8/26/2013, Vol. 24 Issue 163, p2 

    This section offers biopharmaceutical industry news briefs as of August 2013, including the transfer of recombinant Annexin A5 product rights to Medirista AB by Athera Biotechnologies AB, acceptance of a Paragraph IV certification letter by Intelgenx Corp. from Wockhardt Bio AG, and extension of...

  • Hologic challenges KV over Makena. Weinstein, Deborah // Medical Marketing & Media;Nov2012, Vol. 47 Issue 11, p21 

    The article focuses on the move of Hologic Inc., who sold KV Pharmaceutical Co. the rights to Makena, a drug approved for the prevention of premature birth, to accuse KV for botching the marketing and to acquire the rights to the drug.

  • Troubled K-V Pharmaceutical Restructures, Files Bankruptcy. Shaffer, Catherine // BioWorld Today;8/7/2012, Vol. 23 Issue 152, p1 

    The article reports on the filing for Chapter 11 bankruptcy protection of K-V Pharmaceutical Co. in the U.S. Bankruptcy Court for the Southern District of New York. The bankruptcy filing is aimed at restructuring the company's financial obligations, primarily a milestone payment to Hologic Inc....

  • Santaris Getting $10M Up Front In BMS Drug Discovery Pact. Sheridan, Cormac // BioWorld International;4/17/2013, Vol. 18 Issue 16, p2 

    The article reports on a multiproduct drug discovery alliance signed by Santaris Pharma A/S with biopharmaceutical firm Bristol-Myers Squibb Co. The deal involves Santaris' Locked Nucleic Acid (LNA) antisense technology. Under the alliance, Santaris will receive 10 million U.S. dollars up front...

  • GSK Picks a Side in MiR-122 IP Battle; Inks Regulus HCV Deal. Boggs, Jennifer // BioWorld Today;2/26/2010, Vol. 21 Issue 38, p1 

    The article reports that the pharmaceutical company GlaxoSmithKline plc (GSK) and biopharmaceutical company Regulus Therapeutics Inc. have partnered in a 150 million U.S. dollar venture to develop an miR-122 antagonist in hepatitis C virus. Prior to this deal, GSK declined an option for SPC3649,...

  • Santaris Gets $700M From GSK In Antiviral LNA-Based Drug Pact. Sheridan, Cormac // BioWorld Today;12/20/2007, Vol. 18 Issue 246, p1 

    The article reports that Santaris Pharma A/S in Copenhagen, Denmark has formed a drug discovery and development alliance with GlaxoSmithKline PLC (GSK) in London, England. It states that the deal involves a total of five programs, including one on an ongoing program in hepatitis C virus...

  • GSK and Santaris to develop antiviral drugs.  // PharmaWatch: Biotechnology;Feb2008, Vol. 7 Issue 2, p13 

    The article reports on the worldwide strategic alliance between GlaxoSmithKline (GSK) and Santaris Pharma A/S for the development and commercialization of novel medicines against viral diseases in the U.S. The Santaris Pharma will grant GSK options to drug candidates discovered and developed...

  • Global Deals Network.  // BioPharm International;Jan2008, Vol. 21 Issue 1, p14 

    The article provides information related to agreements of biopharmaceutical companies in 2007. GlaxoSmithKline agreed with Santaris Pharma A/S for the discovery, development, and commercialization of novel medicines against viral diseases. Fovea Pharmaceuticals SA entered into a collaborative...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics